Anticipated $0.81 EPS for Eagle Pharmaceuticals, Inc. (EGRX) on May, 14

April 17, 2018 - By Eula Gilbert

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s quarterly earnings will be reported On May, 14., as reported by Faxor. Analysts predict $0.81 EPS. That’s $0.61 down or 42.96 % from 2017’s earnings of $1.42. In case of $0.81 EPS EGRX’s profit could be $12.04M. -3.57 % negative EPS growth is what analysts predict. $0.84 EPS was reported for last [previous quarter]. The stock increased 0.99% or $0.53 during the last trading session, reaching $54.09.Currently Eagle Pharmaceuticals, Inc. is downtrending after 36.05% change in last April 17, 2017. EGRX has 7,861 shares volume. The stock underperformed the S&P 500 by 47.60%.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Coverage

Total analysts of 3 have positions in Eagle Pharmaceuticals (NASDAQ:EGRX) as follows: 2 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 67%. Since October 26, 2017 according to StockzIntelligence Inc Eagle Pharmaceuticals has 7 analyst reports. On Tuesday, January 30 the rating was maintained by Piper Jaffray with “Buy”. On Thursday, October 26 Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating. Mizuho has “Sell” rating and $37.0 target. On Monday, February 26 the rating was maintained by Mizuho with “Sell”. On Wednesday, March 21 the firm has “Sell” rating by Mizuho given. On Sunday, November 5 the stock has “Buy” rating by RBC Capital Markets. The stock rating was maintained by RBC Capital Markets with “Buy” on Monday, February 26. On Monday, December 18 the stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Sell” rating by Mizuho.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.The firm is worth $803.89 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.16.54 is the P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.